We aim to evaluate patients’ expectations about the impact of immunotherapy on their health related quality of life and their actual quality of life. We will also be able to assess the quality of life in elderly patients, and those with multiple comorbidities (ECOG performance status at baseline between 0 to 2 ),when being treated with immunotherapy, as there are few studies evaluating the health related quality of life in these two subgroups